Sign in →

Test Code LABLBC Lamellar Body Count, Amniotic Fluid

Additional Codes

Test Name in EPIC EPIC Test Code Mnemonic Mayo Test ID


Reporting Name

Lamellar Body Count, AF

Useful For

Predicting fetal lung maturity and assessing the risk of developing neonatal respiratory distress syndrome, when performed during 32 to 39 weeks gestation

Method Name

Sysmex XN-9000, Platelet Count by Impedance Method

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type

Amniotic Fld

Specimen Required

Container/Tube: Amniotic fluid container or plastic vial

Specimen Volume: 2 mL

Collection Instructions:

1. Do not centrifuge

2. Amniotic specimens must be blood and meconium free.

Specimen Minimum Volume

0.75 mL

Specimen Stability Information

Specimen Type Temperature Time
Amniotic Fld Refrigerated (preferred) 28 days
  Ambient  7 days

Reject Due To


Mild reject; Gross reject






Centrifuged specimen. Presence of blood or meconium

Reference Values

Immature: <15,000/mcL

Indeterminate: 15,000-50,000/mcL

Mature: >50,000/mcL


Cutoffs are based on consensus protocol (Neerhof M, Dohnal JC, Ashwood ER, et al: Lamellar body counts: a consensus on protocol. Obstet Gynecol 2001;97:318-320)

Day(s) and Time(s) Performed

Monday through Sunday; Continuously

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
LBC Lamellar Body Count, AF 19114-8


Result ID Test Result Name Result LOINC Value
LBCC Lamellar Body Count 19114-8
LBCI Interpretation In Process

Specimen Retention Time

2 weeks


Surfactant secretion into the amniotic fluid is minimal prior to 32 weeks gestation.


Fetal lung maturity testing is not indicated beyond week 39.


Specimens must not be frozen or centrifuged. Freezing and centrifuging the amniotic fluid falsely decreases the lamellar body count.

Method Description

The Sysmex Automated Hematology Analyzer XN-9000 measures platelet count by the impedance method to quantify lamellar body counts.(Automated Hematology Analyzer/Transportation units XN series [XN-9000] Instructions for Use [North American Edition], Sysmex Corporation, Kobe, Japan. Feb 2014)


Amniotic fluid lamellar body counts (LBC) above 50,000/mcL are predictive of fetal lung maturity.


Amniotic fluid LBC below 15,000/mcL are suggestive of fetal lung immaturity and increased risk of neonatal respiratory distress syndrome (RDS).


The main value of fetal lung maturity testing is predicting the absence of RDS. An immature test result for fetal lung maturity is less reliable in predicting the presence of RDS.(1)

Clinical Information

Fetal lung maturity testing is used to determine the risk for developing respiratory distress syndrome (RDS) in infants born prematurely (32-39 weeks). The risk for developing RDS is inversely related to gestational age and is the most common cause of respiratory failure in neonates. RDS is associated with preterm birth due to insufficient production of pulmonary surfactant. Pulmonary surfactant is synthesized by type II pneumocytes. Surfactant consists of 90% phospholipids (primarily phosphatidylcholine and phosphatidylglycerol) and 10% proteins (surfactant proteins [SP]-A, SP-B, SP-C). Surfactant is packaged into lamellar bodies and is excreted into the alveolar space where it unravels and forms a monolayer on alveolar surfaces. Lamellar bodies can also pass into the amniotic cavity and, hence, are found in amniotic fluid. The surfactant functions to reduce the surface tension in the alveoli, preventing atelectasis. When surfactant is deficient, the small alveoli collapse and the large alveoli become overinflated and stiff, which has been associated with increased risk of developing respiratory distress. The status of fetal lung maturity is reflected in the concentration of surfactant in the form of phospholipids and lamellar bodies present in amniotic fluid. Lamellar bodies are similar in size to platelets and can be quantified on a hematology analyzer utilizing the platelet channel and used to estimate fetal lung maturity.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Analytic Time

Same day/1 day